Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study

Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, studies comparing different biologics are lacking. We evaluated the QoL in patients with severe asthma comprehensively and c...

Full description

Saved in:
Bibliographic Details
Published in:The World Allergy Organization journal 2024-09, Vol.17 (9), p.100957, Article 100957
Main Authors: Rhyou, Hyo-In, Kim, Hyun-Kyoung, Song, Woo-Jung, Lee, Sang Min, Kim, Sang-Ha, Kwon, Jae-Woo, Park, Han-Ki, Park, Hye-Kyung, Kim, Sang Hoon, Choi, Jeong-Hee, Kim, Sujeong, Park, So-Young, Kim, Sae-Hoon, Moon, Ji-Yong, Jung, Jae-Woo, Cho, Young-Joo, Park, Chan Sun, Kim, Byung Keun, Kim, Joo-Hee, Yang, Min-Suk, Kim, Min-Hye, Nam, Young-Hee, Lee, Taehoon, Lee, Byung-Jae, Bhavsar, Pankaj, Adcock, Ian M., Chung, Kian Fan, Kim, Tae-Bum
Format: Article
Language:English
Subjects:
Anti-IL-4/IL-13
Anti-IL-5
Biologics
Full Length
Quality of life
Severe asthma
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, studies comparing different biologics are lacking. We evaluated the QoL in patients with severe asthma comprehensively and compare the efficacy of different T2-directed biologics using QoL questionnaires. We compared the QoL between severe and mild-to-moderate asthma and between severe asthma with and without biologics treatment. Data of mild-to-moderate were extracted from the Cohort for Reality and Evolution of Adult Asthma in Korea, and data of severe asthma were collected from the Precision Medicine Intervention in Severe Asthma. We included 183 patients with severe asthma treated with T2 biologics or conventional therapy between April 2020 and May 2021 and assessed QoL of them using the Questionnaire for Adult Korean Asthmatics (QLQAKA), Severe Asthma Questionnaire (SAQ), and EuroQoL-5Dimensions (EQ-5D) at baseline and 6 months. The EQ-5D index (0.803) of severe asthma was lower than that of other chronic diseases representing a worse QoL. The scores for all questions of QLQAKA, except “cough,” were lower (less control) in the severe asthma group than in the mild-to-moderate asthma group at baseline and 6 months (P 
ISSN:1939-4551
1939-4551
DOI:10.1016/j.waojou.2024.100957